Live prices from 3 SA suppliers, from R400.00, compared side by side so you never overpay.
Copy the code — you'll paste it at checkout.
with our exclusive code
You're about to visit an external supplier
with our exclusive code
By clicking "Continue", you acknowledge that you understand and accept the above. Read our full disclosure.
Compare 2 prices for Adipotide. Cheapest: R699.00. Average: R724.50.
| Compare | Visit | |||||||
|---|---|---|---|---|---|---|---|---|
JP Research
Best
Adipotide |
R699.00 | R139.80/mg | In Stock | Free |
Lab Tested
|
— | ||
|
Adipotide 5mg |
R750.00 | R150.00/mg | Out of Stock | R250.00 |
—
|
— |
More ways to compare Adipotide
Different views of the same live SA pricing, tuned for how you like to shop.
Compare another peptide
All purchases are made directly from third-party suppliers; your relationship is solely with them. We accept no liability for the quality, purity, or legality of any products listed.
We may earn a commission when you click through to a supplier and make a purchase. This does not affect pricing information displayed.
By using this site you accept responsibility for ensuring purchases comply with applicable laws in your jurisdiction. Read our full disclosure.
Prohibitin-Targeting Peptidomimetic | Experimental Anti-Obesity
Chimeric adipose-vasculature-targeted peptidomimetic targeting prohibitin/annexin A2 on white adipose tissue endothelium, delivering pro-apoptotic D-(KLAKLAK)2 motif. In obese primates it produced rapid fat loss with improved insulin resistance, yet development halted after Phase 1 due to kidney safety signals.
CKGGRAKDC ligand homes to prohibitin/annexin A2 on white-fat endothelium; linked D-(KLAKLAK)2 disrupts mitochondrial membranes post-internalization, triggering localized endothelial apoptosis and adipocyte loss.
CKGGRAKDC-GG-D(KLAKLAK)2
Selective white adipose tissue vascular targeting produced 7-15% body-weight loss over 4 weeks in obese macaques.
Improved insulin response (reduced insulin AUC) following fat-mass reduction in primates.
Weight loss without primary appetite suppression; peripheral vascular approach.
Rapid fat-mass reduction in obese non-human primates with improved insulin sensitivity; direct white adipose tissue vascular targeting.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Primate Research Replication | 0.43 mg/kg | Once daily | SubQ |
| Dose-Finding (Research) | 0.10-0.75 mg/kg | Once daily (escalating tiers) | SubQ |
Potential additive dehydration/GI effects; monitor renal function.
Overlapping weight-loss effects; monitor kidney function, volume status, electrolytes.
No clinical data on co-administration; mechanisms differ.
No published data on combined use or pharmacodynamic interaction.
No known direct interaction; distinct mechanisms and targets.
Metabolic effects may confound body-composition endpoints.
Theoretical vascular/pressor effects; stagger dosing, monitor BP and hydration.
Adipotide shows dose-dependent proximal tubule injury; avoid additional renal insults.
Early reduction in abdominal circumference
Progressive weight/fat-mass decline
Partial rebound possible; lab signals include mild creatinine rise and electrolyte shifts
Rhesus macaques at 0.43 mg/kg SC daily for 28 days showed 7.4-14.7% weight loss; insulin resistance improved; mild, dose-dependent, reversible proximal tubule changes.
Mice with diet-induced obesity showed ~30% weight reduction; adipose vascular apoptosis; metabolic normalization.
Mechanistic validation of prohibitin/ANXA2 axis in adipose tissue, core to TP01 targeting.
Next-generation prohibitin constructs improve serum stability and efficacy vs. first-generation TP01.
Be the first to know when prices drop on your favourite peptides
No spam. Unsubscribe anytime. We respect your privacy.